Skip to main content

Table 1 Clinicopathologic characteristics, preoperative systemic inflammatory response markers, and postoperative metastatic pattern of patients with stage III colon cancer

From: Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer

Variable

Overall [cases (%)]

High PNI group [cases (%)]

Low PNI group [cases (%)]

P value

Total

274

152 (55.5)

122 (44.5)

 

Age (years)

 ≤ 60

189 (69.0)

112 (73.7)

77 (63.1)

0.061

 > 60

85 (31.0)

40 (26.3)

45 (36.9)

 

Sex

0.274

 Male

156 (56.9)

91 (59.9)

65 (46.7)

 

 Female

118 (43.1)

61 (40.1)

57 (53.3)

 

Baseline BMI (kg/m2)

0.154

 < 18.5

28 (10.2)

11 (7.2)

17 (13.9)

 

 18.5–25.0

187 (68.2)

105 (69.1)

82 (67.2)

 

 > 25.0

59 (21.5)

36 (23.7)

23 (18.9)

 

Hemoglobin (g/L)

< 0.001

 < 90

42 (15.3)

11 (7.2)

31 (25.4)

 

 ≥ 90

232 (84.7)

141 (92.8)

91 (74.6)

 

Tumor location

< 0.001

 Right-sided colon

103 (37.6)

44 (28.9)

59 (48.4)

 

 Left-sided colon

171 (62.4)

108 (71.1)

63 (51.6)

 

Tumor size (cm)

< 0.001

 ≤ 4

140 (51.1)

91 (59.9)

49 (40.2)

 

 > 4

134 (48.9)

61 (40.1)

73 (59.8)

 

Differentiation

0.962

 Well/moderate

207 (75.5)

115 (75.7)

92 (75.4)

 

 Poor/undifferentiated

67 (24.5)

37 (24.3)

30 (24.6)

 

T stage

0.754

 T1–T2

12 (4.4)

6 (3.9)

6 (4.9)

 

 T3

121 (44.2)

70 (46.1)

51 (41.8)

 

 T4

141 (51.5)

76 (50.0)

65 (53.3)

 

N stage

0.762

 N1

189 (69.0)

106 (69.7)

83 (68.0)

 

 N2

85 (31.0)

46 (30.3)

39 (32.0)

 

TNM stage

0.290

 IIIA

10 (3.6)

6 (3.9)

4 (3.3)

 

 IIIB

202 (73.7)

117 (77)

85 (69.7)

 

 IIIC

62 (22.6)

29 (19.1)

33 (27.0)

 

Preoperative serum CEA level (ng/mL)

0.031

 ≤ 5

159 (58.0)

97 (63.8)

62 (50.8)

 

 > 5

115 (42.0)

55 (36.2)

60 (49.2)

 

Cycles of XELOX adjuvant chemotherapya

0.296

 < 6

53 (19.3)

26 (17.1)

27 (22.1)

 

 6–8

221 (80.7)

126 (82.9)

95 (77.9)

 

LMR

 

 ≤ 4.00

144 (52.6)

59 (38.8)

85 (69.7)

< 0.001

 > 4.00

130 (47.4)

93 (61.2)

37 (30.3)

 

NLR

 

 ≤ 2.05

134 (48.9)

90 (59.2)

44 (36.1)

< 0.001

 > 2.05

140 (51.1)

62 (40.8)

78 (63.9)

 

PLR

 

 ≤ 142.99

134 (48.9)

102 (67.1)

32 (26.2)

< 0.001

 > 142.99

140 (51.1)

50 (32.9)

90 (73.8)

 

Postoperative metastasisb

53 (19.3)

22 (14.5)

31 (25.4)

0.024

Liver metastasis

21 (7.7)

9 (5.9)

12 (9.8)

0.231

Lung metastasis

12 (4.4)

5 (3.3)

7 (5.7)

0.331

Abdominopelvic metastasis

16 (5.9)

5 (3.3)

11 (9.0)

0.053

  1. PNI prognostic nutritional index, BMI body mass index, TNM stage clinical tumor-node-metastasis stage, CEA carcinoembryonic antigen, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio
  2. aXELOX adjuvant chemotherapy was administrated as follow: oxaliplatin 130 mg/m2 administered intravenously on day 1 and capecitabine 1000 mg/m2 administered orally twice daily on days 1–14 for a 3-week cycle
  3. bThe metastatic sites of 4 patients were not recorded
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us